Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function
Matthias Gijsen,Omar Elkayal,Pieter Annaert,Ruth Van Daele,Philippe Meersseman,Yves Debaveye,Joost Wauters,Erwin Dreesen,Isabel Spriet
DOI: https://doi.org/10.2147/IDR.S343264
2022-01-08
Infection and Drug Resistance
Abstract:Matthias Gijsen, 1, 2 Omar Elkayal, 1 Pieter Annaert, 1, 3 Ruth Van Daele, 1, 2 Philippe Meersseman, 4 Yves Debaveye, 4 Joost Wauters, 4 Erwin Dreesen, 1 Isabel Spriet 1, 2 1 Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; 2 Pharmacy Department, University Hospitals Leuven, Leuven, Belgium; 3 BioNotus, Niel, Belgium; 4 Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium Correspondence: Matthias Gijsen Pharmacy Department, University Hospitals Leuven, Herestraat 49, Leuven, 3000, Belgium Tel +32 16 340087 Fax +32 16 343080 Email Purpose: Critically ill patients with preserved or increased renal function have been shown to be at risk of underexposure to meropenem. Although many meropenem population pharmacokinetic (PK) models have been published, there is no large prospective population PK study with rich sampling focusing on patients most at risk of suboptimal pharmacokinetic/pharmacodynamic (PK/PD) target attainment. Therefore, the aim of the present study was to evaluate PK/PD target attainment and to perform a thorough covariate screening using population PK modelling of meropenem in septic patients with preserved or increased renal function. Patients and Methods: A single-centre prospective observational PK study was performed in the intensive care unit (ICU) of the University Hospitals Leuven. Patients with severe sepsis or septic shock and treated with meropenem in the ICU were screened for inclusion. Patients were excluded if they received renal replacement therapy or had an estimated glomerular filtration rate according to the Chronic Kidney Disease Epidemiology collaboration equation 1-4xMIC ) are recommended for optimal bacterial killing and to avoid emergence of antimicrobial resistance. 9,11 Several studies have shown that conventional meropenem dosing regimens may lead to unacceptable PK/pharmacodynamic (PK/PD) target attainment -Abstract Truncated-
pharmacology & pharmacy,infectious diseases